Genetic Technologies benefits from Healthy China Policy
Genetic Technologies (ASX:GTG), a provider of world-leading genetic risk assessment test products, has announced the establishment of its Asian operations within the Hainan Resort Software Community (HRSC) Free Trade Zone.
The company’s move into Asia includes the formation of Genetic Technologies HK Limited (the Hong Kong holding company investment vehicle) and Hainan Aocheng Genetic Technologies Co. Ltd (HAGTCL).
Genetic Technologies has had significant success as an early-stage biotech with its proprietary BREVAGenplus clinically validated assessment test for non-hereditary breast cancer being a first to market product.
The company has had four patents granted in the US, with six pending that relate to breast cancer risk assessment, including markers for breast cancer and methods for genetic and genomic analysis.
With regard to the HAGTCL investment vehicle, it will operate from within the Medical Pilot Zone established in what is known as “the Hainan Smart City”, a precinct that already includes many world renowned technology companies.
Participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market valued in excess of US$800 billion.
Companies approved to operate in China as part of the Hainan Free Trade Zone initiative can take advantage of significant tax benefits, subsidies and facilitated investment.
The underlying government policy supporting this initiative is important for a company such as Genetic Technologies, as its ‘Healthy China 2030 Policy’ demonstrates a commitment to investing in research that aims to achieve ‘prevention is better than the cure’ style of health outcomes.
Support from government and regulatory bodies
The Hainan Provincial Government has established a world-class technology zone in Hainan and Genetic Technologies is delighted to be one of only a few medical technology invitees to date.
In addition, the HRSC will also support the company’s Chinese market entry through the provision of a range of services.
These include office space in the Free Trade Zone precinct and complementary accommodation for company staff.
As well as receiving Chinese corporate registry support, Genetic Technologies would also be entitled to marketing assistance, providing a link with government sectors, hospitals and other Chinese based health enterprises.
Support in gaining FDA approval
Importantly, assistance would also be provided in obtaining China FDA approval for the group’s new and growing portfolio of genetic risk assessment tests, substantially fast tracking the pathway to sales process.
Genetic Technologies’ researchers would also benefit from access to test samples from the Chinese ethnic population, facilitating new product development.
The establishment of operations follows on from the formal invitation to Genetic Technologies from the Hainan Provincial Government received in August 2018.
At this stage, it was envisaged that a joint venture with Zishan would form part of its China initiative, however the joint venture approach will not be progressing at this time.
Instead, Genetic Technologies, through its wholly-owned subsidiary HAGTCL, will work to introduce its world-class genetic risk assessment tests to the Chinese market.
Facilitation of collaborative opportunities
Commenting on the benefits of the joint venture agreement, Paul Kasian, Genetic Technologies’ chairman and chief executive said, “This initiative is likely to include partnering with Chinese health and medical distribution companies and CFDA accredited genetic testing laboratory operations.
“The Hainan Provincial Government team will help us find appropriate collaboration partners in mainland China.
“The establishment of operations in Hainan China is a significant step to advance the adoption of genetic risk assessment tests in China and in due course other parts of Asia.
“We are grateful for the support we have received from HRSC to date and acknowledge their commitment to continue to work with GTG to provide a meaningful contribution to the Healthy China 2030 Policy.”
Genetic Technologies will be paying its part in growing the suite of world-leading genetic risk assessment test products that will become central to China’s future preventative medicine activities.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.